Toolgen said Thursday that it would become a global leader in gene editing platforms and gene and cell therapy products based on its superior technology after joining the secondary Kosdaq market.The company, now traded on the smaller Konex market, seeks to move to the bigger Kosdaq market by offerin
Daiichi Sankyo Korea said its hypertension drug Sevikar HCT (ingredient: amlodipine, olmesartan medoxomil, hydrochlorothiazide) showed promising long-term efficacy and safety profile for Korean patients with essential hypertension in RESOLVE-PRO clinical trial.RESOLVE-PRO trial is a real-world study
Celltrion said Wednesday that it would supply Covid-19 antibody treatment, Regkirona (ingredient: regdanvimab), to more facilities treating patients with lighter symptoms to help curb its spread. “Following the decision by Korea Disease Control and Prevention Center (KDCA) to expand the supply of Re
Novartis’ anticancer drug targeting MET mutation in non-small cell lung cancer obtained approval in Korea.On Tuesday, the Ministry of Food and Drug Safety authorized the use of Tabrecta (ingredient: capmatinib), an oral MET inhibitor, for the treatment of patients with locally advanced or metastatic
SillaJen said on Tuesday that it started administering Pexa-Vec, an oncolytic virus therapy, in a phase 1b/2 trial to patients with melanoma in China. The Korean biotech firm is conducting the study jointly with its Chinese partner, Lee’s Pharm.The phase 1b study in China will be on 46 patients with
FedEx Express said it has been selected as “Asia’s best third-party logistics (3PLs) for vaccines” at the Asia Pacific Vaccine Excellence Awards 2021.The award was attributed to the transportation company’s protection of shipment integrity and the supply of vaccines across the globe.FedEx has transp
Aduhelm (ingredient: aducanumab), developed by Biogen and authorized by the FDA as the first treatment for Alzheimer’s disease, is engulfed in controversy.The new Alzheimer’s drug recently reported the death of a patient who died of amyloid-related imaging abnormalities (ARIA), the most common side
Three Korean pharmaceutical companies are in a fierce race to develop a biosimilar of Stelara (ustekinumab), a treatment for autoimmune diseases.Samsung Bioepis, Celltrion, and Dong-A ST have received authorization to conduct global phase 3 trials of Stelara biosimilars.Recently, Dong-A ST finished
As the Covid-19 pandemic continues, there are growing calls to increase the self-sufficiency of pharmaceutical raw materials in Korea.The call for self-sufficiency of pharmaceutical raw materials has recently increased after the nation has been making a flurry of diplomatic efforts to secure urea an
Genexine said Friday that the company expects its Covid-19 vaccine candidate, GX-19N, to prevent infection for a long time as it uses T cell immune response instead of antibodies.GX-19N, a DNA vaccine, is a next-generation vaccine with nucleocapsid antibody added to the existing spike protein protec
Sanofi’s Dupixent (dupilumab), a severe atopic dermatitis (AD) treatment covered by health insurance in people aged 18 or more, should become reimbursable for adolescents, too, a petition on Cheong Wa Dae said.Dupixent is the only biologic agent that can treat severe AD. In addition, it proved thera
JW Pharmaceutical said that it would cooperate with Syntekabio in developing innovative new drugs based on artificial intelligence.Under the accord, the two companies will expand the scope of existing joint research to discover first-in-class candidate materials that target specific disease-causing
Genome & Company said that it would build a large-scale microbiome production facility in Fishers City, Indiana, U.S., through its local offshoot, List Biotherapeutics.The company established List Biotherapeutics in October last year. Biotherapeutics plans to build a large-scale microbiome productio
Ildong Pharmaceutical said Wednesday it has decided to jointly develop S-217622, a candidate material for oral Covid-19 treatment, with Shionogi Pharmaceutical, a Japanese drugmaker.The drug candidate, developed by Shionogi, is a substance developed for treating Covid-19 orally by taking the drug
COREE Company, a member of Hanmi Science Consortium, has signed a strategic partnership agreement with Infini Fluidic of the U.S. to develop a new method in the microfluidic process producing mRNA vaccine lipid nanoparticle structures.Hanmi Science CEO Lim Jong-yoon also serves as the president of C
BioLeaders said its Covid-19 treatment candidate under joint development with the Korea Mouse Phenotyping Center has shown effective results against the Delta variant in a recent study.The company also conducted a secondary evaluation of the candidate drug’s efficacy at Seoul National University Bun
Cellid, one of the local developers of a homegrown Covid-19 vaccine, updated its plan for a local, late-stage trial.“Our latest plan for a phase 2b trial benchmarked Janssen’s discussion for a booster shot. We have yet to confirm two doses of the vaccine, but this is one of the many possibilities to
Yuhan Corp. said it received 11.8 billion won ($9.97 million) of milestone payment as its non-alcoholic steatohepatitis (NASH) therapy licensed out to Boehringer Ingelheim entered the global phase 1 trial.Boehringer Ingelheim has paid Yuhan a total of $50 million as milestone payments since it signe
Voronoi said it has licensed out VRN08, a monopolar spindle 1 (MPS1)-targeted solid cancer treatment, to Pyramid Biosciences, a U.S. biotech company.Under the accord, Voronoi will receive up to a total of $846 million in milestone payments from Pyramid Biosciences. However, the company did not unvei
Korea Pharma said it has concluded a deal to receive the transfer of production technology of iron deficiency anemia therapy, Accrufer (ingredient: ferric maltol), from the U.K.-based Shield Therapeutics.On Tuesday, shield Therapeutics Vice Presidents David Childs and Jackie Mitchell visited Korea P